Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q03013

UPID:
GSTM4_HUMAN

ALTERNATIVE NAMES:
GST class-mu 4; GST-Mu2; GSTM4-4; Leukotriene C4 synthase GSTM4

ALTERNATIVE UPACC:
Q03013; A8K765; Q05465; Q32NC1; Q4JNT8; Q6FH87

BACKGROUND:
The enzyme Glutathione S-transferase Mu 4, also referred to as GSTM4-4, is integral to the body's defense mechanism against toxic substances. It does so by attaching reduced glutathione to various exogenous and endogenous compounds, thereby neutralizing them. Its activity includes the synthesis of leukotriene C4, a critical mediator in inflammatory responses, and the production of MCTR1, a bioactive lipid with profound anti-inflammatory effects.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Glutathione S-transferase Mu 4 unveils promising avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.